• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Tango Therapeutics Inc.

    9/13/24 5:43:22 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TNGX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001688327
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Tango Therapeutics, Inc.
    SEC File Number
    001-39485
    Address of Issuer
    201 BROOKLINE AVENUE
    SUITE 901
    BOSTON
    MASSACHUSETTS
    02215
    Phone
    (857) 320-4900
    Name of Person for Whose Account the Securities are To Be Sold
    Third Rock Ventures IV, L.P.
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Affiliate

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    BTIG, LLC
    350 Bush St.
    9th floor
    San Francisco � CA � 94104
    67400707700.0010714446509/13/2024
    NASD


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/23/2017Pre-IPOPurchased from TRV IIICheckbox not checked6740003/23/2017Wire

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Third Rock Ventures IV, L.P.
    201 Brookline Ave
    Suite 1401
    Boston � MA � 02215
    Common07/17/20245501715386339.14
    Third Rock Ventures IV, L.P.
    201 Brookline Ave
    Suite 1401
    Boston � MA � 02215
    Common07/18/20241914901878478.60
    Third Rock Ventures IV, L.P.
    201 Brookline Ave
    Suite 1401
    Boston � MA � 02215
    Common07/22/20242627402570096.41
    Third Rock Ventures IV, L.P.
    201 Brookline Ave
    Suite 1401
    Boston � MA � 02215
    Common07/23/20241250001223350.00
    Third Rock Ventures IV, L.P.
    201 Brookline Ave
    Suite 1401
    Boston � MA � 02215
    Common07/24/20242000001963160.00
    Third Rock Ventures IV, L.P.
    201 Brookline Ave
    Suite 1401
    Boston � MA � 02215
    Common07/25/2024100599992771.29
    Third Rock Ventures IV, L.P.
    201 Brookline Ave
    Suite 1401
    Boston � MA � 02215
    Common07/26/202450000491950.00
    Third Rock Ventures IV, L.P.
    201 Brookline Ave
    Suite 1401
    Boston � MA � 02215
    Common07/30/202495000931114.00
    Third Rock Ventures IV, L.P.
    201 Brookline Ave
    Suite 1401
    Boston � MA � 02215
    Common07/31/2024100000993380.00
    Third Rock Ventures IV, L.P.
    201 Brookline Ave, Suite 1401
    Boston � MA � 02215
    Common08/01/202440000392000.00
    Third Rock Ventures IV, L.P.
    201 Brookline Ave
    Suite 1401
    Boston � MA � 02215
    Common08/16/20241350001321447.50
    Third Rock Ventures IV, L.P.
    201 Brookline Ave
    Suite 1401
    Boston � MA � 02215
    Common08/19/20241500001513920.00
    Third Rock Ventures IV, L.P.
    201 Brookline Ave
    Suite 1401
    Boston � MA � 02215
    Common08/27/202425000288665.00
    Third Rock Ventures IV, L.P.
    201 Brookline Ave
    Suite 1401
    Boston � MA � 02215
    Common08/30/20241750002029702.50
    Third Rock Ventures IV, L.P.
    350 Bush St.
    9th floor
    San Francisco � CA � 94104
    Common09/05/202475000867135.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    09/13/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Kevin Gillis

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $TNGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNGX

    DatePrice TargetRatingAnalyst
    11/18/2025Peer Perform
    Wolfe Research
    8/19/2025$11.00Overweight
    Piper Sandler
    7/17/2024$19.00Buy
    Jefferies
    4/4/2024Overweight
    Cantor Fitzgerald
    2/12/2024$18.00Overweight
    Piper Sandler
    12/8/2023$16.00Buy
    B. Riley Securities
    10/20/2022$10.00Neutral → Buy
    H.C. Wainwright
    9/20/2021$25.00Outperform
    SVB Leerink
    More analyst ratings

    $TNGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Tango Therapeutics

    Wolfe Research initiated coverage of Tango Therapeutics with a rating of Peer Perform

    11/18/25 8:28:20 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Tango Therapeutics with a new price target

    Piper Sandler initiated coverage of Tango Therapeutics with a rating of Overweight and set a new price target of $11.00

    8/19/25 8:36:26 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Tango Therapeutics with a new price target

    Jefferies initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $19.00

    7/17/24 8:01:05 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

    BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 2:00 PM EST. The live webcast will be available under the "Events & Presentations" tab on the "Investors" page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discover

    2/3/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

    Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the company's founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters, a

    1/8/26 9:05:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Appoints Sung Lee to Board of Directors

    BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Mr. Sung Lee to the Board of Directors. Mr. Lee has over 20 years of experience in finance leadership in the biopharmaceutical and technology industries. "We are delighted to welcome Sung Lee to our Board of Directors," said Barbara Weber, M.D., Chief Executive Officer of Tango Therapeutics. "Sung's proven track record in corporate strategy, investor relations and finance will be instrumental as we advance our lead program, vopimetostat, into reg

    1/5/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Beckman Daniella sold $126,531 worth of shares (10,317 units at $12.26) and was granted 44,330 shares, increasing direct ownership by 23% to 184,297 units (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    2/4/26 8:12:01 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director, Executive Chair Weber Barbara was granted 37,522 shares and sold $374,294 worth of shares (30,519 units at $12.26), increasing direct ownership by 0.43% to 1,629,254 units (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    2/4/26 8:09:06 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, R&D Crystal Adam was granted 47,460 shares and sold $226,300 worth of shares (18,452 units at $12.26), increasing direct ownership by 18% to 187,218 units (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    2/4/26 8:02:17 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Tango Therapeutics Inc.

    SCHEDULE 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

    2/10/26 4:15:01 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Tango Therapeutics Inc.

    SCHEDULE 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)

    2/6/26 4:11:47 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Tango Therapeutics Inc.

    SCHEDULE 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

    1/30/26 2:44:14 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rothenberg Mace bought $74,000 worth of shares (20,000 units at $3.70), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    11/18/24 7:20:03 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4) (Amendment)

    4/A - Tango Therapeutics, Inc. (0001819133) (Issuer)

    10/17/23 7:41:18 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    10/17/23 6:04:34 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Leadership Updates

    Live Leadership Updates

    View All

    Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

    Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the company's founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters, a

    1/8/26 9:05:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Appoints Sung Lee to Board of Directors

    BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Mr. Sung Lee to the Board of Directors. Mr. Lee has over 20 years of experience in finance leadership in the biopharmaceutical and technology industries. "We are delighted to welcome Sung Lee to our Board of Directors," said Barbara Weber, M.D., Chief Executive Officer of Tango Therapeutics. "Sung's proven track record in corporate strategy, investor relations and finance will be instrumental as we advance our lead program, vopimetostat, into reg

    1/5/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

    – Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors – – FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA1/2-mutant breast and ovarian cancer; phase 1/2 clinical trial initiation expected 1H 2024 – – Kanishka Pothula, partner at Nextech Ventures, appointed to Board of Directors, replacing Reid Huber, Ph.D., partner at Third Rock Ventures – – Strong cash position of $360 million; cash runway into 2026 expected to fund all clini

    11/8/23 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Financials

    Live finance-specific insights

    View All

    Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

    BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cance

    10/29/25 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

    – 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% –  – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 –  – 49% ORR and mPFS 9.1 months in histology agnostic cohort of multiple late line, difficult to treat cancers provide further evidence of strong activity – – Company to hold conference call today at 8:30am ET –  BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced positive data from its ongoing Phase 1/2 stud

    10/23/25 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

    BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report second quarter 2025 financial results on August 5, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more in

    7/22/25 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tango Therapeutics Inc.

    SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

    11/20/24 4:24:26 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

    SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

    11/7/24 9:35:56 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

    SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

    10/28/24 9:22:40 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care